Marianne Ellen Pavel



Organisation


Professur für Endokrinologie
Medizinische Klinik 1 - Gastroenterologie, Pneumologie und Endokrinologie
Medizinische Fakultät


Publications (Download BibTeX)

Go to first page Go to previous page 1 of 5 Go to next page Go to last page

Pavel, M.E., Phan, A.T., Wolin, E.M., Mirakhur, B., Liyanage, N., Pitman Lowenthal, S.,... Vinik, A.I. (2019). Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors. Oncologist, 24(4), 463-474. https://dx.doi.org/10.1634/theoncologist.2018-0217
Felder, S., Jann, H., Arsenic, R., Denecke, T., Prasad, ., Knappe-Drzikova, B.,... Pape, U.F. (2019). Gastric neuroendocrine neoplasias: manifestations and comparative outcomes. Endocrine-Related Cancer, 26(9), 751-763. https://dx.doi.org/10.1530/ERC-18-0582
Yao, J., Garg, A., Chen, D., Capdevila, J., Engstrom, P., Pommier, R.,... Kulke, M.H. (2019). Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials. Endocrine-Related Cancer, 26(4), 391-403. https://dx.doi.org/10.1530/ERC-18-0332
Busse, A., Spenke, C., Arsenic, R., Briest, F., Sipos, B., Kaemmerer, D.,... Grabowski, P. (2019). Immunoprofiling in Neuroendocrine Neoplasms: Implications for Immunotherapy. In NEUROENDOCRINOLOGY (pp. 5-5). BASEL: KARGER.
Semrau, S., Agaimy, A., Pavel, M.E., Lubgan, D., Schmidt, D., Cavallaro, A.,... Fietkau, R. (2019). Long-term control with chemoradiation of initially metastatic mixed adenoneuroendocrine carcinoma of the rectum: A case report. Journal of Medical Case Reports, 13(1). https://dx.doi.org/10.1186/s13256-019-1995-x
Anthony, L., Kulke, M., Caplin, M., Bergsland, E., Oberg, K., Pavel, M.E.,... Jiang, W. (2019). Long-Term Follow Up of Patients With Carcinoid Syndrome Diarrhea Treated With Telotristat Ethyl: A Pooled Analysis of Phase 2 and 3 Trials. In PANCREAS (pp. 428-428). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
Pavel, M.E., Borson-Chazot, F., Cailleux, A., Hoersch, D., Lahner, H., Pivonello, R.,... Ferone, D. (2019). Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study. Cancer Chemotherapy and Pharmacology, 83(2), 375-385. https://dx.doi.org/10.1007/s00280-018-3734-1
Fehrenbach, U., Kahn, J., Fahlenkamp, U., Baur, A., Pavel, M.E., Geisel, D., & Denecke, T. (2019). Optimized imaging of the lower abdomen and pelvic region in hepatocyte-specific MRI: evaluation of a whole-abdomen first-pass shuttle protocol in patients with neuroendocrine neoplasms. Acta Radiologica, 60(9), 1074-1083. https://dx.doi.org/10.1177/0284185118817936
Graf, J., Pape, U.F., Jann, H., Denecke, T., Arsenic, R., Brenner, W.,... Prasad, V. (2019). Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE. European Journal of Nuclear Medicine and Molecular Imaging. https://dx.doi.org/10.1007/s00259-019-04439-9
Pavel, M.E., Dromain, C., Thanh, T.X.M., & Houchard, A. (2019). Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/Depot (LAN) for Pts with Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: Prospective, Open-label, International, Phase 2 CLARINET FORTE Study. In NEUROENDOCRINOLOGY (pp. 157-157). BASEL: KARGER.

Last updated on 2019-23-01 at 11:22